You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME / ABIM MOC / CE

Are Individuals With Cancer Discussing Fertility Options?

  • Authors: News Author: Roxanne Nelson, RN, BSN; CME Author: Laurie Barclay, MD
  • CME / ABIM MOC / CE Released: 10/30/2020
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 10/30/2021
Start Activity


Target Audience and Goal Statement

This article is intended for hematologists/oncologists, gastroenterologists, internists, obstetricians/gynecologists/ women's health practitioners, nurses, surgeons, and other members of the healthcare team who treat and manage people of reproductive age who have cancer.

The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  • Evaluate rates of fertility preservation counseling and referrals to reproductive specialists among patients of reproductive age before starting chemotherapy, as well as factors associated with these rates, based on a cross-sectional study using survey data from the American Society of Clinical Oncology Quality Oncology Practice Initiative
  • Assess the clinical implications of fertility preservation counseling and referrals to reproductive specialists among patients of reproductive age before starting chemotherapy, based on a cross-sectional study using survey data from the American Society of Clinical Oncology Quality Oncology Practice Initiative
  • Outline implications for the healthcare team


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


News Author

  • Roxanne Nelson, RN, BSN

    Journalist, Medscape Oncology

    Disclosures

    Disclosure: Roxanne Nelson, RN, BSN, has disclosed no relevant financial relationships.

CME Author

  • Laurie Barclay, MD

    Freelance writer and reviewer, Medscape, LLC

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

Nurse Planner

  • Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE

    Associate Director, Accreditation and Compliance
    Medscape, LLC

    Disclosures

    Disclosure: Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE, has disclosed no relevant financial relationships.

Editor/CME Reviewer

  • Esther Nyarko, PharmD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships. 


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Are Individuals With Cancer Discussing Fertility Options?

Authors: News Author: Roxanne Nelson, RN, BSN; CME Author: Laurie Barclay, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 10/30/2020

Valid for credit through: 10/30/2021

processing....

Clinical Context

As cancer survival increases, quality of life, including fertility preservation, is an increasing concern for patients. Chemotherapy and radiotherapy are both effective cancer treatments but have persistent adverse effects on the reproductive system in both sexes.

For patients of reproductive age with newly diagnosed cancer, the opportunity to discuss fertility preservation is therefore crucial before starting chemotherapy or other treatment, as recommended by the American Society for Reproductive Medicine and the American Society of Clinical Oncology (ASCO). The goal of this cross-sectional study using survey data from the ASCO Quality Oncology Practice Initiative was to identify factors associated with fertility preservation counseling and referrals to reproductive specialists among patients of reproductive age before starting chemotherapy.

Study Synopsis and Perspective

Less than half of patients with cancer who are of reproductive age receive fertility counseling, despite guidelines recommending that these discussions be had with every eligible patient.

The findings come from the largest study on this subject to date. Researchers surveyed nearly 7000 patients with cancer who were reproductive age. The study was published online July 17 in JAMA Network Open.

Only 44% of patients with cancer reported having had a discussion with their clinician about the risk for infertility associated with chemotherapy, the study found. Clinicians were more likely to discuss the risk for infertility with female patients than male patients, as well as with younger patients.

One reason these discussions are not being held is because of time constraints, commented lead author Ranjith Ramasamy, MD, director of male reproductive medicine and surgery and an associate professor in the Department of Urology at the University of Miami, Florida.

"There is so much to discuss when a patient is first diagnosed with cancer," he told Medscape Medical News. "The patient wants to know about the treatment -- the different options, the side effects, prognosis, insurance coverage -- and fertility preservations gets pushed to the wayside.

"Providers often do not have the time or the resources to have these discussions, and the best solution is to make a referral to a specialist," said Dr Ramasamy. "It's not a big issue to do this, and the office staff can all play a very important role in arranging a referral."

He added that at his institution, making a referral for fertility preservation comes up as a best practice alert through the electronic medical records system.

Dr Ramasamy emphasized the importance of bringing up this topic, especially with younger patients. "About 75% to 80% of adolescents diagnosed with cancer are surviving, and it is incumbent upon doctors that we think about the future," said Dr Ramasamy. "Even if they're not thinking about it now, they may want a family in the future."

For several reasons, fertility is often overlooked by patients and physicians when cancer is first diagnosed, but as survival increases, so does the importance of future quality of life. The American Society for Reproductive Medicine and ASCO both recommend that clinicians discuss fertility preservation with adult and pediatric patients before the initiation of anticancer therapy.

Less Counseling for Men and for Older Patients

For their study, Dr Ramasamy and colleagues used data obtained from the ASCO Quality Oncology Practice Initiative. They identified 6976 patients as being of reproductive age, ranging from 18 to 40 years for women (n = 3405) and from 18 to 50 years for men (n = 3571).

Within this group, 3036 patients (44%) received counseling about the risk for infertility that was associated with their treatment. Women were more likely to be counseled (56%) than men (32%; P<.001).

Younger patients were more likely to be counseled. The frequency of discussions concerning infertility risk declined as the patient age increased (odds ratio [OR], 0.91; P<.001). Race/ethnicity did not appear to have an effect on the frequency of discussions (Black: OR, 1.03; Asian: OR, 1.14; Hispanic: OR, 1.04; other or not reported: OR, 0.99).

Overall, factors that were associated with a lower likelihood of having this discussion included male sex (OR, 0.73), increasing age (OR, 0.93), private practice setting (OR, 0.70), and a lack of a multidisciplinary team (OR, 0.54). Factors that were associated with a higher likelihood of discussion included having breast cancer (OR, 1.39) and lymphatic or hematopoietic cancers (OR, 1.79), treatment in an academic setting (OR, 1.45), and the practice's offering clinical trial enrollment (OR, 1.60).

Insurance may not cover the cost of fertility preservation, which may present a barrier for many patients. As of 2019, 5 states had passed laws that mandate coverage. In those states, patients were more often counseled or referred to a fertility specialist after the laws went into effect.

Barriers to Referral

Approached by Medscape Medical News for an independent comment, Maryam B. Lustberg, MD, MPH, associate professor of medicine and medical director of cancer support services, the Ohio State Comprehensive Cancer Center, Columbus, believes that these conversations are not happening for a number of reasons. These include a lack of time, a lack of awareness, competing priorities because of the need to treat an aggressive cancer quickly, assumptions as to what patients want and need and a failure to engage in shared decision making, and a lack of resources and access to fertility preservation counseling and services.

"A new diagnosis requires a lot of discussion points, and both patients and providers can feel overwhelmed to cover and take in all of these points," said Dr Lustberg. "If fertility is mentioned quickly in passing, the patient and family may not have time to process the information and may initially say they are not interested."

Another reason is that some oncologists may not be as aware of guidelines or assume some patients may not be able to afford the services or want the services. "Disparities in care due to socioeconomic and race are also a consideration," she said. "Additionally, some oncologists may make assumptions that patients with advanced cancers may not want to discuss this issue and therefore not bring it up."

Dr Lustberg also pointed out that there are some barriers to making referrals. "Navigators in young adult care and fertility preservation are definitely helpful and increase referrals, but not all oncology practices may have access to these," she said. "Virtually delivering counseling services to practices that may not have this will be helpful, and we are working toward implementing this type of services."

This study was funded by the Department of Urology, University of Miami Miller School of Medicine. The authors have disclosed no relevant financial relationships. Dr Lustberg has relationships with PledPharma, Disarm Therapeutics, and Hologic/Cynosure.

JAMA Netw Open. Published online July 17, 2020.[1]

Study Highlights

  • This cross-sectional study used data from the ASCO Quality Oncology Practice Initiative, an oncologist-led quality assessment program surveying approximately 400 oncology practices biannually, from January 2015 to June 2019.
  • Discussion before starting chemotherapy regarding reproductive risks was the primary outcome.
  • Factors associated with fertility preservation counseling were identified with multivariate logistic regression, which allowed controlling for age, sex, race/ethnicity, cancer type, year of study, region, clinic type (academic vs private), annual clinic volume, and rates of insurance coverage.
  • Reproductive age was defined as 18 to 40 years for women and 18 to 50 years for men.
  • Of 6976 patients of reproductive age; 51% were men; mean age was 42.5±7.1 years.
  • Only 3036 (44%) of 6976 patients received counseling regarding the risk for infertility associated with chemotherapy.
  • Women were more likely than men to receive counseling (56% vs. 32%; P<.001).
  • Factors linked to reduced likelihood of fertility risk discussion included male sex (OR, 0.73; 95% confidence interval [CI], 0.60-0.90), increasing age (OR, 0.93; 95% CI, 0.92-0.94), private practice setting (OR, 0.70; 95% CI, 0.53-0.93), lack of multidisciplinary team planning (OR, 0.54; 95% CI, 0.41-0.70), and low percentage of insurance coverage within a clinic.
  • Surprisingly, multispecialty clinics had lower rates of fertility risk counseling than did single specialty clinics.
  • Factors linked to increased likelihood of fertility risk discussion included breast cancer (OR, 1.39; 1.12-1.73), lymphatic or hematopoietic cancer (OR, 1.79; 95% CI, 1.33-2.40), participation in each subsequent study year (OR, 1.16; 95% CI, 1.08-1.24), academic clinic setting (OR, 1.45; 95% CI, 1.05-2.01), and availability of clinical trial enrollment (OR, 1.60; 95% CI, 1.13-2.29).
  • Even when controlling for private vs academic status, clinics offering clinical trials had higher rates of discussions regarding fertility risks of chemotherapy.
  • Rates of fertility risk discussion were significantly higher in states with vs without legislatively mandated coverage of fertility preservation (48.6% vs 39.6%; P<.001).
  • Race/ethnicity was not significantly associated with rates of fertility counseling.
  • On the basis of their findings, the investigators concluded that clinicians are more likely to counsel younger patients and women about reproductive risks before starting chemotherapy.
  • State laws mandating fertility preservation coverage and academic centers compared with private practice settings may be linked to greater likelihood of receiving fertility counseling before chemotherapy.
  • Academic institutions may expedite collaboration between oncologists and reproductive specialists, as may multidisciplinary team planning and clinical trial availability.
  • Oncologists likely understand the association of chemotherapy and radiotherapy with fertility, but many may be unaware of contemporary options for fertility preservation.
  • Other barriers to fertility counseling may include lack of clinician time, greater emphasis on the need for prompt treatment, faulty assumptions regarding patient needs, failure to engage in shared decision making, and lack of resources and access to fertility preservation counseling and services.
  • To improve rates of fertility risk discussion and referrals to fertility specialists before the onset of chemotherapy, the investigators recommend greater awareness, dissemination, and implementation of ASCO guidelines and quality measures; ongoing educational initiatives between oncologists and fertility specialists; and additional research on unique barriers that may exist in private practice oncology settings.
  • The investigators suggest that the routine practice of oncology should include protecting options for future parenthood at the time of diagnosis with cancer and appropriate referral to a reproductive specialist.
  • Similar findings from a Japanese study highlight the need both in the United States and elsewhere to identify strategies to increase fertility education and indicated referrals to fertility specialists for adult patients with newly diagnosed cancers.
  • Lower rates of fertility risk counseling in multispecialty vs single specialty clinics might be attributed to unclear delineation of which provider is responsible for such counseling.
  • More rigorous oversight, informed consent, and internal institutional guidelines in clinics offering clinical trials may facilitate or expedite fertility counseling.
  • In facilities where clinicians are deficient on quality metrics, quality improvement initiatives are needed to improve rates of fertility risk discussion and referrals for fertility preservation, as well as routine use of ASCO Quality Oncology Practice Initiative quality data to track resulting improvements.
  • Quality initiatives may include electronic medical record prompts for patients meeting criteria for fertility discussion and/or referral.
  • As clinicians were more likely to counsel younger patients and female patients, equitable patient care requires efforts to reduce these biases.
  • As states with mandated coverage for fertility preservation had better rates of fertility discussion and referral, the investigators encourage advocacy efforts to ensure passage of similar laws in other states to improve patient access to reproductive health.
  • Study limitations include lack of patient data regarding reproductive history, reliance on self-report from oncology practices regarding infertility risk and preservation counseling, and lack of data for patients younger than 18 years or for those undergoing radiotherapy or surgery.

Clinical Implications

  • Less than half of patients of reproductive age with cancer receive fertility counseling or referral before starting chemotherapy, with even lower rates in older patients and men, according to a cross-sectional study using survey data from the ASCO Quality Oncology Practice Initiative.
  • To improve rates of fertility risk discussion and referrals to fertility specialists before the onset of chemotherapy, the investigators recommend greater awareness, dissemination, and implementation of ASCO guidelines and quality measures; ongoing educational initiatives between oncologists and fertility specialists; and additional research on unique barriers that may exist in private practice oncology settings.
  • Implications for the Healthcare Team: The investigators suggest that the routine practice of oncology should include protecting options for future parenthood at the time of diagnosis with cancer and appropriate referral to a reproductive specialist.

 

Earn Credit

  • Print